title: Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab.
abstract: The authors report refractive errors possibly resulting from intravitreal bevacizumab injection. Triplet A presented with stage 3 retinopathy of prematurity, was treated with intravitreal bevacizumab, and high refractive errors were noted. Triplet B presented with stage 2 retinopathy of prematurity in the right eye and stage 3 retinopathy of prematurity in the left eye, which regressed spontaneously. Triplet C presented with stage 2 retinopathy of prematurity in the right eye and stage 3 retinopathy of prematurity in the left eye, which were treated with intravitreal bevacizumab.
authors.affiliation: Department of Ophthalmology, Changhua Christian Hospital, Changhua, Taiwan.
authors.forename: Chien-Chi
authors.initials: CC
authors.lastname: Tseng
authors.forename: San-Ni
authors.initials: SN
authors.lastname: Chen
authors.forename: Jiunn-Feng
authors.initials: JF
authors.lastname: Hwang
authors.forename: Chun-Ju
authors.initials: CJ
authors.lastname: Lin
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D005260:Female; D005865:Gestational Age; D006801:Humans; D006956:Hyperopia / Q000139:chemically induced* / Q000175:diagnosis; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D058449:Intravitreal Injections; D008297:Male; D009216:Myopia / Q000139:chemically induced* / Q000175:diagnosis; D012178:Retinopathy of Prematurity / Q000145:classification / Q000188:drug therapy*; D014310:Triplets; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab